Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Autor:
Luis Puig, Jose Bernabeu-Wittel, Ignasi Gich, Monica Rios, María Teresa Montserrat-García, Eulalia Baselga, Fania Zamantta Muñoz-Garza, Esther Roé-Crespo
Publikováno v:
JAMA Dermatol
JAMA DERMATOLOGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
JAMA Dermatology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
JAMA DERMATOLOGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
JAMA Dermatology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
IMPORTANCE: Treatment of infantile hemangioma (IH) with topical timolol in the first 2 months of life (early proliferative phase) may prevent further growth and the need for treatment with oral propranolol. To our knowledge, no studies have determine
Autor:
Jake J. Lee, John S. Schneider, Dorina Kallogjeri, Jay F. Piccirillo, Murali M. Chakinala, Andrew M. Peterson
Publikováno v:
JAMA Otolaryngol Head Neck Surg
Importance Other than nasal moisturizers, no standard-of-care medical therapy exists for epistaxis in hereditary hemorrhagic telangiectasia (HHT). With epistaxis as the greatest cause of morbidity in patients with HHT, there is a need to identify eff
Autor:
Nina A. Karaseva, Sukrut Shah, Lucjan Wyrwicz, Joseph Chao, Christian Caglevic, Kohei Shitara, Luis Villanueva, Eric Van Cutsem, Al B. Benson, Eray Goekkurt, Wasat Mansoor, Marcelo Garrido, Iveta Kudaba, Keun Wook Lee, Jeeyun Lee, Maria Alsina, Andrew H. Ko, Charles S. Fuchs, S. Peter Kang, Josep Tabernero, Hugo Castro, Hironaga Satake, Uma Kher, Yung-Jue Bang, Maria Ignez Braghiroli, Peter C. Enzinger, Zev A. Wainberg, Hyun Cheol Chung
Publikováno v:
JAMA Oncology. 6:1571
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alo
Autor:
Zoe B. Ciantra, Shana Criscitiello, Jason I. Kass, Jochen H. Lorch, Roy B. Tishler, Kai W. Wucherpfennig, Glenn J. Hanna, Nicole G. Chau, Adrienne M. Luoma, Ravindra Uppaluri, Danielle N. Margalit, Heather A. Jacene, Donald J. Annino, Anupam M. Desai, Bhupendra Rawal, Brendan Ross, Robert I. Haddad, Vickie Y. Jo, Jason L. Weirather, Ana Lako, Yu-Hui Chen, P.S. Catalano, Jonathan D. Schoenfeld, Hina Shah, Laura A. Goguen, Scott J. Rodig
Publikováno v:
JAMA Oncology. 6:1563
Importance Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and combining programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte
Autor:
Martin Sökler, Ulrich Keller, Carsten Kobe, Bastian von Tresckow, Andreas Rosenwald, Stephan Mathas, Paul J Bröckelmann, Michael Fuchs, Jasmin Mettler, Julia Meissner, Peter Borchmann, Andrea Kerkhoff, Andreas Zimmermann, Stephanie Sasse, Wolfram Klapper, Helen Goergen, Rainer Ordemann, Andreas Engert, Matthias Bormann, Teresa V Halbsguth, Christian Baues, Andreas Hüttmann
Publikováno v:
JAMA Oncol
Importance In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but ha
Autor:
Natasha Flowers, Steven T. Bird, Donna Przepiorka, Barry W. Miller, Zebulin Kessler, Corinne Woods, Clara Kim, Tae-Hyun Jung, Bo Kim, Kate Gelperin, David J. Graham, Michael Wernecke, Thomas E. MaCurdy, Stephen McKean, Jeffrey A. Kelman, Rongrong Wang, Fang Tian
Publikováno v:
JAMA Oncol
Idelalisib (IDEL) is approved as monotherapy in relapsed follicular lymphoma (FL) and with rituximab (IDEL+R) for relapsed chronic lymphocytic leukemia (CLL). Toxic effects can be severe and treatment-limiting. Outcomes in a real-world population are
Autor:
Jessica K Roydhouse, Richard Pazdur, Rajeshwari Sridhara, Pallavi S. Mishra-Kalyani, Laurel A. Menapace, Paul G. Kluetz, Julia A. Beaver, Gideon M. Blumenthal, Daniel L. Suzman
Publikováno v:
JAMA Oncol
Importance Regional variation in opioid use may be attenuated when pharmaceutical-sponsored trials include care that is often standardized by protocols. Understanding such variation is important for global trials that sometimes include time to opioid
Autor:
Boang Liu, Shirley Cohen-Mekelburg, Ryan W. Stidham, Akbar K. Waljee, Ji Zhu, Peter D.R. Higgins, Beth I Wallace, Kay Sauder, Yumu Liu
Publikováno v:
JAMA Network Open
Key Points Question Can laboratory data be used to predict durable response to ustekinumab among patients with Crohn disease before they commit to long-term treatment? Findings In this cohort study of 401 participants with active Crohn disease, a pre
Autor:
Francesca Gay, Graham Jackson, Laura Rosiñol, Sarah A. Holstein, Philippe Moreau, Stefano Spada, Faith Davies, Juan José Lahuerta, Xavier Leleu, Sara Bringhen, Andrea Evangelista, Cyrille Hulin, Ugo Panzani, David A. Cairns, Francesco Di Raimondo, Margaret Macro, Anna Marina Liberati, Charlotte Pawlyn, Massimo Offidani, Andrew Spencer, Roman Hájek, Evangelos Terpos, Gareth J. Morgan, Joan Bladé, Pieter Sonneveld, Jesús San-Miguel, Philip L. McCarthy, Heinz Ludwig, Mario Boccadoro, Maria-Victoria Mateos, Michel Attal
Publikováno v:
JAMA Oncology, 4(10), 1389-1397. American Medical Association
GREDOS: Repositorio Institucional de la Universidad de Salamanca
Universidad de Salamanca (USAL)
GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname
GREDOS: Repositorio Institucional de la Universidad de Salamanca
Universidad de Salamanca (USAL)
GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname
Importance Several trials demonstrated the impact of novel agent-based maintenance in newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating the superiority of one regimen over the other, owing to the lack of direct/i
Autor:
Yeung-Chul Mun, James Larkin, Keith T. Flaherty, Edward McKenna, Brigitte Dréno, Qian Zhu, Antoni Ribas, Axel Hauschild, Paolo A. Ascierto, Karl D. Lewis, Grant A. McArthur
Publikováno v:
JAMA Oncology. 4:1382
Importance Prognostic models may provide insight into clinical trial results and inform the clinical management of patients withBRAFV600–mutated metastatic melanoma. Objective To identify subgroups with distinct survival outcomes based on clinical